Given the poor efficacy of currently available treatments in PDAC, pharmacologic inhibitors of IMP3 may represent a viable therapeutic strategy by altering pancreatic cancer cell behavior and halting/delaying pancreatic tumour metastasis. Here, IMP3 is linked to pancreatic neoplasm.